Pre-made Inebilizumab benchmark antibody ( Whole mAb, anti-CD19 therapeutic antibody, Anti-B4/CVID3 Antibody) for drug discovery and mechanism of action (MOA) researchCat No.: GMP-Bios-ab-273
Pre-Made Inebilizumab biosimilar, Whole mAb, Anti-CD19 Antibody: Anti-B4/CVID3 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Inebilizumab, sold under the brand name Uplizna, is a medication for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||List Price(In USD)||Discount off||Discount Price|
Size： 1mg | 10mg | 100mg
|Products Name (INN Index)||Pre-Made Inebilizumab biosimilar, Whole mAb, Anti-CD19 Antibody: Anti-B4/CVID3 therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Approved|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Approved||Neuromyelitis optica|
|Conditions Active||Autoimmune disorders;Myasthenia gravis;Renal transplant rejection|
|Conditions Discontinued||B-cell lymphoma;Chronic lymphocytic leukaemia;Diffuse large B-cell lymphoma;Follicular lymphoma;Multiple myeloma;Multiple sclerosis;Systemic scleroderma|
|Development Tech||POTELLIGENT Technology|